Fifty patients without AF but undergoing cavotricuspid isthmus ablation for recurrent paroxysmal or persistent AFL were assigned to also receive or not receive same-session PVI ablation.

English Edition. Medscape. English; Deutsch; Español; Français; Português; Univadis ...

Medtronic announced the FDA approval of its mapping and dual-energy catheter ablation system for the treatment of persistent atrial fibrillation and radiofrequency ablation of cavotricuspid ...

Patients who underwent radiofrequency ablation were more likely to receive cavotricuspid isthmus ablation (22.8% vs 13.7%), superior vena cava isolation (10.4% vs 4.8%), and left atrial posterior wall ...

The second phase of the trial included the addition of studying the focal FARAPOINT™ Pulsed Field Ablation Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter, ...

Research conducted across 12 hospitals in China has discovered that combining linear ablation with ethanol infusion via the vein of Marshall ... mitral isthmus, and cavotricuspid isthmus.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the Affera™ Mapping and Ablation System with ...

The Sphere-9 catheter (Medtronic) . Medtronic said its PulseSelect system, the first pulsed field ablation device approved by the FDA back in December 2023, will continue to provide a single-shot ...

The second phase of the trial included the addition of studying the focal FARAPOINT™ Pulsed Field Ablation Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter, ...